Liprotamase
drugOn this page
Also known as ALTU-135TheraclecTrizytek
Summary
Liprotamase (CHEMBL2108703) is a phase-3 clinical-stage enzyme; indicated across 2 conditions including exocrine pancreatic insufficiency and cystic fibrosis.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Enzyme
- Indications: 2 conditions
- Clinical trials: 7
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108703 |
| Name | Liprotamase |
| Type | Enzyme |
| Max phase | 3 |
Also known as: ALTU-135, Liprotamase, Theraclec, Trizytek, LIPROTAMASE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| exocrine pancreatic insufficiency | 3 | MONDO:0001684 | MONDO:0001684 |
| cystic fibrosis | 3 | MONDO:0009061 | MONDO:0009061 |
Clinical trials
Total trials: 7.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 5 |
| PHASE4 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02823964 | PHASE4 | COMPLETED | EASY: Extended Access to Sollpura Over Years |
| NCT00449878 | PHASE3 | COMPLETED | Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency |
| NCT00449904 | PHASE3 | COMPLETED | Open-Label Phase III Long-Term Safety Trial of Liprotamase |
| NCT00500084 | PHASE3 | TERMINATED | Phase III ALTU-135 CP Safety Trial |
| NCT02279498 | PHASE3 | COMPLETED | SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis |
| NCT03051490 | PHASE3 | UNKNOWN | RESULT: Reliable, Emergent Solution Using Liprotamase Treatment |
| NCT00095732 | PHASE2 | COMPLETED | Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: exocrine pancreatic insufficiency, cystic fibrosis